Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — Investor Day (June 2025)
11 slides from Fresenius Medical Care's investor day presentation, Jun 17, 2025
Slide 1: Deep-dive breakout session: Artificial Intelligence
Deep-dive breakout session Artificial Intelligence Franklin W. Maddux, MD, Chief Global Medical Officer Len A. Usvyat, PhD, Head of Renal Research Institute London | June 17, 2025 Fresenius Medical Care
Slide 2: Safe harbor statement
Safe harbor statement: In this Safe harbor statement, “the Company” and “Fresenius Medical Care” refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conve
Slide 3: Leveraging the power of vertical integration to Reignite FME
Leveraging the power of vertical integration to Reignite FME Clinics recognize Care Care Provide customer needs to drive Delivery Enablement differentiated innovation in technology therapies to clinics €14.0bn Medical value creation €5.6bn Revenue 2024 Revenue 2024 Patient data & insights, future in
Slide 4: AI @ FME | Accelerating the journey
AI @ FME | Accelerating the journey 2019 Seamless AI 2025+ integration ~2000 Ubiquitous AI integration links products and services through medical Data and analytics innovation, clinic operations and foundation business optimization through world- class expertise and unmatched data assets 2024 Estab
Slide 5: FME advantage in AI and advanced medicine | Uniquely positioned to drive innovation
FME advantage in AI and advanced medicine | Uniquely positioned to drive innovation Driving operational ns to External Academia and S ctio cien efficiencies onne ce C elopment Ap m atic Dev pro rag ach P Advanced Unparalleled Analytics and Data Assets Digital Expertise ertical Integration V Medical
Slide 6: FME advantage in AI and advanced medicine | Unique data assets
FME advantage in AI and advanced medicine | Unique data assets Leveraging 7 petabytes of clinical data to achieve the most comprehensive view of the patient 2.7m 770m 2.1bn 1.9bn HD in-center patients labs treatments medications Every 10 seconds, we gather 170 MB of data from our machines, translati
Slide 7: FME's evolution of computational medicine innovation
FME’s evolution of computational medicine innovation Today FME stands at the forefront of a revolution in healthcare, uniquely progressing to fully automated clinical intelligence An innovation pathway few others can replicate Co-pilots Auto-pilots Guidelines Working on “co-pilot” Going to “auto-pil
Slide 8: Examples of current and future AI applications
Examples of current and future AI applications Development >3 dozen tools and solutions focused on phase Stage 1 Stage 2 Stage 3 Stage 4 clinical and medical innovation Product development Service delivery Value-based care Examples Examples Examples Stage AskHUGO clinical companion ▪ Access360: AI m
Slide 9: AI example | Access care through data driven algorithms
AI example | Access care through data driven algorithms Access360: AI models across the access continuum STAGE 4 STAGE 1 AVF END OF LIFECYCLE PRE-PLACEMENT Model assesses intervention-free survival 4 1 AI identifies metabolomic pattern for AVF. Supports surgical decision making in pre-surgery plasma
Slide 10: We lead kidney care through exceptional patient care and innovation
We lead kidney care through exceptional patient care and innovation Fresenius Medical Care
Slide 11: Contacts
Contacts Fresenius Medical Care AG Investor Relations Else-Kröner-Str. 1 61352 Bad Homburg v. d. H. Germany Dr. Dominik Heger Ilia Kuerten Alicia Cahill ir@FreseniusMedicalCare.com Head of Investor Relations Vice President Senior Director and Investor Relations Investor Relations Ticker: Head of I